Panacea Biotec Ltd

Securities in F&O Ban: Sammaan Capital and Steel Authority of India shares are banned from F&O trading on 13 April 2026. Result Today: ICICI Prudential Asset Management Company, Just Dial, Swaraj Engines, Innovision, Parin Enterprises, Indbank Housing and Continental Controls will announce their quarterly earnings today. IPO Opening: Om Power reported 0.71x subscription on Day 2 Om Power's initial public offering (IPO) was subscribed 0.71 times overall on Day 2 (as of 5:00 PM), with Qualified Institutional Buyers (QIBs) subscribing 1.18 times, the retail portion at 0.58 times, and Non-Institutional Investors (NIIs) at 0.38 times. Stocks to Watch: Panacea Biotec announced that it has received a letter of award (LoA) worth Rs 20.79 crore from Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India. Advance Agrolife announced that it has received a letter of intent (LoI) worth Rs 30.37 crore from National Fertilizers for the supply of various agrochemicals. Zaggle Prepaid Ocean Services announced that it has entered into an agreement with Generali Central Insurance Company (formerly known as Future Generali India Insurance Company Limited) to provide its Zaggle Zoyer platform. Emerald Leisures said that it has received a letter of intent (LoI) for the development of a residential redevelopment project at Swastik Park, Chembur in Mumbai, with an estimated revenue potential of around Rs 600 crore. Larsen & Toubro said its real estate arm, L&T Realty Properties, has acquired a 100% stake in International Green Scapes for Rs 1,123 crore in an all-cash deal, as it looks to expand its residential portfolio in Gurugram. Airfloa Rail Technology said that it has secured a domestic order worth Rs 1.25 crore from Rail Coach Factory Kapurthala for the supply of luggage rack modules for LHB non-AC and AC chair car coaches. Blue Dart Express reported a low-severity cyber security incident within its parent group. The company said the incident involved phishing and impersonation exposure. It clarified that no sensitive data was breached and no customer or business information was impacted. Swiggy's Co-founder Nandan Reddy has stepped down to pursue personal projects, while Chief Growth Officer Phani Kishan and Group CFO Rahul Bothra will join the board as Executive Directors. Laxmi Organic announced that it has appointed Harshvardhan Goenka as Interim CFO following the resignation of Mahadeo Karnik. LIC Housing Finance announced that it has appointed Sanjay Dayal as its Chief Operating Officer (COO).

As per the terms, the company will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents (Td Vaccine) in multiple tranches. The supplies are scheduled to commence from September/October 2026 and continue till November/December 2028. The company clarified that the order has been awarded by a domestic entity and is in the nature of vaccine supply. It further stated that neither its promoters nor promoter group entities have any interest in the awarding authority, and the transaction does not fall under related-party transactions. Panacea Biotec is a research-based biotechnology company engaged in the business of research, development, manufacture, and marketing vaccines in India and international markets. The company reported a consolidated net loss of Rs 7.36 crore in Q3 FY26 as against a net profit of Rs 9.65 crore in Q3 FY25. Revenue from operations declined 8.4% year on year to Rs 99.31 crore in Q3 FY26. Shares of Panacea Biotec rose 1.23% to end at Rs 326 on 10 April 2026.

Panacea Biotec announced that Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 (five) consecutive years as Independent Director on 31 March 2026 and accordingly he has ceased to be an Independent director of the Company.

Net profit of Panacea Biotec declined 11.95% to Rs 3.98 crore in the quarter ended December 2025 as against Rs 4.52 crore during the previous quarter ended December 2024. Sales rose 1.04% to Rs 165.19 crore in the quarter ended December 2025 as against Rs 163.49 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales165.19163.49 1 OPM %7.114.87 - PBDT12.1710.59 15 PBT3.721.61 131 NP3.984.52 -12 Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Under the revision, the contract value for 2026 has been increased by $2.55 million (around Rs 23 crore) to $16.8 million, while the 2027 allocation rises by $2.70 million (around Rs 24 crore) to $15.18 million. Additionally, an extra award for 2027 worth $3.68 million (about Rs 33 crore) has been included, taking the total incremental value to $8.93 million (roughly Rs 80 crore) for the two years. The international supply contract will be executed as per orders received from UNICEF during CY2026 and CY2027. UNICEF is expected to publish details of the award, including supplier name, vaccine, duration, total value, and awarded prices per product on its official website. Panacea Biotec said the award does not involve any promoter or promoter group interest. Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets. The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25. Powered by Capital Market - Live

Vinod Goel (aged ~60 years) is a fellow member of the Institute of Company Secretaries of India and an associate member of the Institute of Cost Accountants of India. He holds B. Com (Hons.), M. Com, and LL. B degrees and has over 35 years of post-qualification experience in corporate governance, finance, legal, M&A, and corporate restructuring. He has been associated with Panacea Biotec since 1999 and currently serves as Group CFO and Head of Legal & Company Secretary. Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets. The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25. Shares of Panacea Biotec shed 0.67% to Rs 354.95 on the BSE.Powered by Capital Market - Live

Net loss of Panacea Biotec reported to Rs 13.92 crore in the quarter ended September 2025 as against net profit of Rs 4.80 crore during the previous quarter ended September 2024. Sales declined 4.22% to Rs 141.13 crore in the quarter ended September 2025 as against Rs 147.35 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales141.13147.35 -4 OPM %-12.614.75 - PBDT-13.5310.67 PL PBT-21.871.99 PL NP-13.924.80 PL Powered by Capital Market - Live

Easyfive TT provides active immunization against severe diseases namely Diphtheria, Haemophilus influenzae type b, Hepatitis-B, Pertussis, and Tetanus. The company will supply Easyfive TT vaccine during calendar year 2026 and 2027. Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26. The counter declined 2.24% to end at Rs 396.40 on Tuesday, 11 November 2025.Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live